We recently published 10 Big Names Leading Wall Street Gains. Sarepta Therapeutics Inc. is one of the best-performing stocks on Wednesday.
Sarepta saw its share price jump by 15.25 percent on Wednesday to close at $18.67 apiece as investors took heart from an investment company’s bullish rating for its stock.
In a market note, Mizuho Securities raised its rating for Sarepta Therapeutics Inc. to “outperform” from “neutral” while raising its price target by 36.8 percent to $26 from $19 previously. The new figure marked a 39 percent upside potential from its latest closing price.
Mizuho said the upgrade was based on its confidence in the Elevidys drug—a prescription therapy to treat over four-year-old patients with Duchenne muscular dystrophy—having raked in $131.5 million in sales in just the third quarter, and well ahead of its $50 million target, despite reports of deaths linked to the drug.
Meanwhile, Sarepta Therapeutics Inc. swung to a net loss of $180 million in the period July to September, reversing a $33.6 million net income in the same period last year.
Revenues dropped by 14.5 percent to $399 million from $467 million year-on-year, amid lower revenues from Elevidys as a result of the shipping suspension in June 2025 due to the death reports.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
